

## CONFLICT-OF-INTEREST STATEMENT

David Dorn has not received fees for serving as a speaker.

David Dorn has only received research funding from the state and his home institution.

David Dorn is solely an employee of his home institution.

David Dorn owns no stocks and/or shares.

David Dorn owns patents to:

1) Synthesis of epothilones, intermediates thereto, analogues and uses thereof  
Patent number: 7384964

2) Migrastatin analogs in the treatment of cancer  
Patent number: 8957056

3) Isomigrastatin analogs in the treatment of cancer  
Patent number: 8188141



David C. Dorn

28.03.2015